<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> is an <z:hpo ids='HP_0000006'>autosomal dominant</z:hpo> disease characterized by <z:hpo ids='HP_0001363'>craniosynostosis</z:hpo> and bony <z:hpo ids='HP_0001159'>syndactyly</z:hpo> associated with point mutations (S252W and P253R) in the fibroblast growth factor receptor (FGFR) 2 that cause FGFR2 activation </plain></SENT>
<SENT sid="1" pm="."><plain>Here we investigated the role of the S252W mutation of FGFR2 on osteoblastic differentiation </plain></SENT>
<SENT sid="2" pm="."><plain>Osteoblastic cells derived from digital bone in two <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert</z:e> patients with the S252W mutation showed more prominent alkaline phosphatase activity, osteocalcin and osteopontin <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression, and mineralized nodule formation compared with the control osteoblastic cells derived from two independent non-syndromic <z:hpo ids='HP_0010442'>polydactyly</z:hpo> patients </plain></SENT>
<SENT sid="3" pm="."><plain>Stable clones of the human MG63 <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> cells (MG63-Ap and MG63-IIIc) overexpressing a splice variant form of FGFR2 with or without the S252W mutation (FGFR2IIIcS252W and FGFR2IIIc) showed a higher RUNX2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression than parental MG63 cells </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore MG63-Ap exhibited a higher osteopontin <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression than did MG63-IIIc </plain></SENT>
<SENT sid="5" pm="."><plain>The enhanced osteoblastic marker gene expression and mineralized nodule formation of the MG63-Ap was inhibited by the conditioned medium from the COS-1 cells overexpressing the soluble FGFR2IIIcS252W </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore the FGF2-induced osteogenic response in the mouse calvarial organ culture system was blocked by the soluble FGFR2IIIcS252W </plain></SENT>
<SENT sid="7" pm="."><plain>These results show that the S252W mutation in the FGFR2 gene enhances the osteoblast phenotype in human osteoblasts and that a soluble FGFR2 with the S252W mutation controls osteoblast differentiation induced by the S252W mutation through a dominant negative effect on FGFR2 signaling in <z:e sem="disease" ids="C0001193" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Apert syndrome</z:e> </plain></SENT>
</text></document>